Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,9338908,terminal elimination half-life,"The terminal elimination half-life in serum was about 3.5-4.0 hours and 6 hours for ropivacaine and bupivacaine, respectively.",Comparative local anesthetic efficacy and pharmacokinetics of epidurally administered ropivacaine and bupivacaine in the sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9338908/),h,3.5-4.0,8044,DB00961,Mepivacaine
,9338908,terminal elimination half-life,"The terminal elimination half-life in serum was about 3.5-4.0 hours and 6 hours for ropivacaine and bupivacaine, respectively.",Comparative local anesthetic efficacy and pharmacokinetics of epidurally administered ropivacaine and bupivacaine in the sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9338908/),h,6,8045,DB00961,Mepivacaine
,2907021,tmax,"Our data showed significant 24 h variations in the following parameters: Highest tmax value = 0.366 +/- 0.073 h at 1000 h (P less than 0.005, amplitude, maximum-minimum/mean x 100, = 184%), highest Cmax/tmax ratio = 177.17 +/- 9.49 at 2200 h (P less than 0.005, amplitude = 192%), highest Vd = 0.842 +/- 0.23 L kg-1 at 2200 h (P less than 0.005, amplitude = 158%) and highest beta phase elimination half-life = 5.408 +/- 1.36 h at 2200 h (P less than 0.025, amplitude = 145%).",Circadian phase-dependent pharmacokinetics and acute toxicity of mepivacaine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907021/),h,0.366,10726,DB00961,Mepivacaine
,2907021,Cmax/tmax ratio,"Our data showed significant 24 h variations in the following parameters: Highest tmax value = 0.366 +/- 0.073 h at 1000 h (P less than 0.005, amplitude, maximum-minimum/mean x 100, = 184%), highest Cmax/tmax ratio = 177.17 +/- 9.49 at 2200 h (P less than 0.005, amplitude = 192%), highest Vd = 0.842 +/- 0.23 L kg-1 at 2200 h (P less than 0.005, amplitude = 158%) and highest beta phase elimination half-life = 5.408 +/- 1.36 h at 2200 h (P less than 0.025, amplitude = 145%).",Circadian phase-dependent pharmacokinetics and acute toxicity of mepivacaine. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907021/),,177.17,10727,DB00961,Mepivacaine
,2907021,Vd,"Our data showed significant 24 h variations in the following parameters: Highest tmax value = 0.366 +/- 0.073 h at 1000 h (P less than 0.005, amplitude, maximum-minimum/mean x 100, = 184%), highest Cmax/tmax ratio = 177.17 +/- 9.49 at 2200 h (P less than 0.005, amplitude = 192%), highest Vd = 0.842 +/- 0.23 L kg-1 at 2200 h (P less than 0.005, amplitude = 158%) and highest beta phase elimination half-life = 5.408 +/- 1.36 h at 2200 h (P less than 0.025, amplitude = 145%).",Circadian phase-dependent pharmacokinetics and acute toxicity of mepivacaine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907021/),[l] / [kg],0.842,10728,DB00961,Mepivacaine
,2907021,beta phase elimination half-life,"Our data showed significant 24 h variations in the following parameters: Highest tmax value = 0.366 +/- 0.073 h at 1000 h (P less than 0.005, amplitude, maximum-minimum/mean x 100, = 184%), highest Cmax/tmax ratio = 177.17 +/- 9.49 at 2200 h (P less than 0.005, amplitude = 192%), highest Vd = 0.842 +/- 0.23 L kg-1 at 2200 h (P less than 0.005, amplitude = 158%) and highest beta phase elimination half-life = 5.408 +/- 1.36 h at 2200 h (P less than 0.025, amplitude = 145%).",Circadian phase-dependent pharmacokinetics and acute toxicity of mepivacaine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907021/),h,5.408,10729,DB00961,Mepivacaine
,9459249,Peak plasma concentrations,"Peak plasma concentrations of R(+)-bupivacaine (389 +/- 93 ng/mL) and R(-)-mepivacaine (1350 +/- 430 ng/mL) were smaller than those of S(-)-bupivacaine (449 +/- 109 ng/mL, P < 0.0001) and S(+)-mepivacaine (1740 +/- 490 ng/mL, P < 0.002), respectively.",Pharmacokinetics of the enantiomers of bupivacaine and mepivacaine after epidural administration of the racemates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9459249/),[ng] / [ml],389,16732,DB00961,Mepivacaine
,9459249,Peak plasma concentrations,"Peak plasma concentrations of R(+)-bupivacaine (389 +/- 93 ng/mL) and R(-)-mepivacaine (1350 +/- 430 ng/mL) were smaller than those of S(-)-bupivacaine (449 +/- 109 ng/mL, P < 0.0001) and S(+)-mepivacaine (1740 +/- 490 ng/mL, P < 0.002), respectively.",Pharmacokinetics of the enantiomers of bupivacaine and mepivacaine after epidural administration of the racemates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9459249/),[ng] / [ml],1350,16733,DB00961,Mepivacaine
,9459249,Peak plasma concentrations,"Peak plasma concentrations of R(+)-bupivacaine (389 +/- 93 ng/mL) and R(-)-mepivacaine (1350 +/- 430 ng/mL) were smaller than those of S(-)-bupivacaine (449 +/- 109 ng/mL, P < 0.0001) and S(+)-mepivacaine (1740 +/- 490 ng/mL, P < 0.002), respectively.",Pharmacokinetics of the enantiomers of bupivacaine and mepivacaine after epidural administration of the racemates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9459249/),[ng] / [ml],449,16734,DB00961,Mepivacaine
,9459249,Peak plasma concentrations,"Peak plasma concentrations of R(+)-bupivacaine (389 +/- 93 ng/mL) and R(-)-mepivacaine (1350 +/- 430 ng/mL) were smaller than those of S(-)-bupivacaine (449 +/- 109 ng/mL, P < 0.0001) and S(+)-mepivacaine (1740 +/- 490 ng/mL, P < 0.002), respectively.",Pharmacokinetics of the enantiomers of bupivacaine and mepivacaine after epidural administration of the racemates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9459249/),[ng] / [ml],1740,16735,DB00961,Mepivacaine
,9459249,unbound peak concentrations,"However, the unbound peak concentrations of R(+)-bupivacaine (20 +/- 11 ng/mL) were larger than those of S(-)-bupivacaine (15 +/- 9 ng/mL, P < 0.005); unbound peak concentrations of R(-)-mepivacaine (485 +/- 158 ng/mL) and S(+)-mepivacaine (460 +/- 139 ng/mL) did not differ.",Pharmacokinetics of the enantiomers of bupivacaine and mepivacaine after epidural administration of the racemates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9459249/),[ng] / [ml],20,16736,DB00961,Mepivacaine
,9459249,unbound peak concentrations,"However, the unbound peak concentrations of R(+)-bupivacaine (20 +/- 11 ng/mL) were larger than those of S(-)-bupivacaine (15 +/- 9 ng/mL, P < 0.005); unbound peak concentrations of R(-)-mepivacaine (485 +/- 158 ng/mL) and S(+)-mepivacaine (460 +/- 139 ng/mL) did not differ.",Pharmacokinetics of the enantiomers of bupivacaine and mepivacaine after epidural administration of the racemates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9459249/),[ng] / [ml],15,16737,DB00961,Mepivacaine
,9459249,unbound peak concentrations,"However, the unbound peak concentrations of R(+)-bupivacaine (20 +/- 11 ng/mL) were larger than those of S(-)-bupivacaine (15 +/- 9 ng/mL, P < 0.005); unbound peak concentrations of R(-)-mepivacaine (485 +/- 158 ng/mL) and S(+)-mepivacaine (460 +/- 139 ng/mL) did not differ.",Pharmacokinetics of the enantiomers of bupivacaine and mepivacaine after epidural administration of the racemates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9459249/),[ng] / [ml],485,16738,DB00961,Mepivacaine
,9459249,unbound peak concentrations,"However, the unbound peak concentrations of R(+)-bupivacaine (20 +/- 11 ng/mL) were larger than those of S(-)-bupivacaine (15 +/- 9 ng/mL, P < 0.005); unbound peak concentrations of R(-)-mepivacaine (485 +/- 158 ng/mL) and S(+)-mepivacaine (460 +/- 139 ng/mL) did not differ.",Pharmacokinetics of the enantiomers of bupivacaine and mepivacaine after epidural administration of the racemates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9459249/),[ng] / [ml],460,16739,DB00961,Mepivacaine
,3188822,elimination half-life,"Increases in elimination half-life only achieved statistical significance in mepivacaine-treated animals (non-convulsing 45.2 min, convulsing 105.4 min, P less than 0.01).",Alterations in the pharmacokinetic properties of amide local anaesthetics following local anaesthetic induced convulsions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3188822/),min,45.2,30834,DB00961,Mepivacaine
,3188822,elimination half-life,"Increases in elimination half-life only achieved statistical significance in mepivacaine-treated animals (non-convulsing 45.2 min, convulsing 105.4 min, P less than 0.01).",Alterations in the pharmacokinetic properties of amide local anaesthetics following local anaesthetic induced convulsions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3188822/),min,105.4,30835,DB00961,Mepivacaine
,8989005,unbound fraction,The unbound fraction of R(-)-mepivacaine (mean +/- SD: 35.6% +/- 4.5%) was larger (P < 0.0001) than that of S(+)-mepivacaine (25.1% +/- 4.6%).,Pharmacokinetics of the enantiomers of mepivacaine after intravenous administration of the racemate in volunteers. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8989005/),%,35.6,40535,DB00961,Mepivacaine
,8989005,unbound fraction,The unbound fraction of R(-)-mepivacaine (mean +/- SD: 35.6% +/- 4.5%) was larger (P < 0.0001) than that of S(+)-mepivacaine (25.1% +/- 4.6%).,Pharmacokinetics of the enantiomers of mepivacaine after intravenous administration of the racemate in volunteers. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8989005/),%,25.1,40536,DB00961,Mepivacaine
,8989005,total plasma clearance [CL],"The total plasma clearance and steady-state volume of distribution of R(-)-mepivacaine, based on total plasma concentrations (total plasma clearance [CL] = 0.79 +/- 0.12 L/min; volume of distribution at steady state [VSS] = 103 +/- 14 L) as well as on unbound plasma concentrations (plasma clearance of unbound drug [CLu] = 2.24 +/- 0.30 L/min; volume of distribution of unbound drug at steady state [Vuss] = 290 +/- 32 L), were larger (P < 0.0001) than those of S(+)-mepivacaine (CL = 0.35 +/- 0.06 L/min; Vss = 57 +/- 7 L; CLu = 1.43 +/- 0.24 L/ min; Vuss = 232 +/- 30 L).",Pharmacokinetics of the enantiomers of mepivacaine after intravenous administration of the racemate in volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8989005/),[l] / [min],0.79,40537,DB00961,Mepivacaine
,8989005,volume of distribution at steady state [VSS],"The total plasma clearance and steady-state volume of distribution of R(-)-mepivacaine, based on total plasma concentrations (total plasma clearance [CL] = 0.79 +/- 0.12 L/min; volume of distribution at steady state [VSS] = 103 +/- 14 L) as well as on unbound plasma concentrations (plasma clearance of unbound drug [CLu] = 2.24 +/- 0.30 L/min; volume of distribution of unbound drug at steady state [Vuss] = 290 +/- 32 L), were larger (P < 0.0001) than those of S(+)-mepivacaine (CL = 0.35 +/- 0.06 L/min; Vss = 57 +/- 7 L; CLu = 1.43 +/- 0.24 L/ min; Vuss = 232 +/- 30 L).",Pharmacokinetics of the enantiomers of mepivacaine after intravenous administration of the racemate in volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8989005/),l,103,40538,DB00961,Mepivacaine
,8989005,plasma clearance of unbound drug [CLu],"The total plasma clearance and steady-state volume of distribution of R(-)-mepivacaine, based on total plasma concentrations (total plasma clearance [CL] = 0.79 +/- 0.12 L/min; volume of distribution at steady state [VSS] = 103 +/- 14 L) as well as on unbound plasma concentrations (plasma clearance of unbound drug [CLu] = 2.24 +/- 0.30 L/min; volume of distribution of unbound drug at steady state [Vuss] = 290 +/- 32 L), were larger (P < 0.0001) than those of S(+)-mepivacaine (CL = 0.35 +/- 0.06 L/min; Vss = 57 +/- 7 L; CLu = 1.43 +/- 0.24 L/ min; Vuss = 232 +/- 30 L).",Pharmacokinetics of the enantiomers of mepivacaine after intravenous administration of the racemate in volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8989005/),[l] / [min],2.24,40539,DB00961,Mepivacaine
,8989005,volume of distribution of unbound drug at steady state [Vuss],"The total plasma clearance and steady-state volume of distribution of R(-)-mepivacaine, based on total plasma concentrations (total plasma clearance [CL] = 0.79 +/- 0.12 L/min; volume of distribution at steady state [VSS] = 103 +/- 14 L) as well as on unbound plasma concentrations (plasma clearance of unbound drug [CLu] = 2.24 +/- 0.30 L/min; volume of distribution of unbound drug at steady state [Vuss] = 290 +/- 32 L), were larger (P < 0.0001) than those of S(+)-mepivacaine (CL = 0.35 +/- 0.06 L/min; Vss = 57 +/- 7 L; CLu = 1.43 +/- 0.24 L/ min; Vuss = 232 +/- 30 L).",Pharmacokinetics of the enantiomers of mepivacaine after intravenous administration of the racemate in volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8989005/),l,290,40540,DB00961,Mepivacaine
,8989005,CL,"The total plasma clearance and steady-state volume of distribution of R(-)-mepivacaine, based on total plasma concentrations (total plasma clearance [CL] = 0.79 +/- 0.12 L/min; volume of distribution at steady state [VSS] = 103 +/- 14 L) as well as on unbound plasma concentrations (plasma clearance of unbound drug [CLu] = 2.24 +/- 0.30 L/min; volume of distribution of unbound drug at steady state [Vuss] = 290 +/- 32 L), were larger (P < 0.0001) than those of S(+)-mepivacaine (CL = 0.35 +/- 0.06 L/min; Vss = 57 +/- 7 L; CLu = 1.43 +/- 0.24 L/ min; Vuss = 232 +/- 30 L).",Pharmacokinetics of the enantiomers of mepivacaine after intravenous administration of the racemate in volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8989005/),[l] / [min],0.35,40541,DB00961,Mepivacaine
,8989005,Vss,"The total plasma clearance and steady-state volume of distribution of R(-)-mepivacaine, based on total plasma concentrations (total plasma clearance [CL] = 0.79 +/- 0.12 L/min; volume of distribution at steady state [VSS] = 103 +/- 14 L) as well as on unbound plasma concentrations (plasma clearance of unbound drug [CLu] = 2.24 +/- 0.30 L/min; volume of distribution of unbound drug at steady state [Vuss] = 290 +/- 32 L), were larger (P < 0.0001) than those of S(+)-mepivacaine (CL = 0.35 +/- 0.06 L/min; Vss = 57 +/- 7 L; CLu = 1.43 +/- 0.24 L/ min; Vuss = 232 +/- 30 L).",Pharmacokinetics of the enantiomers of mepivacaine after intravenous administration of the racemate in volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8989005/),l,57,40542,DB00961,Mepivacaine
,8989005,CLu,"The total plasma clearance and steady-state volume of distribution of R(-)-mepivacaine, based on total plasma concentrations (total plasma clearance [CL] = 0.79 +/- 0.12 L/min; volume of distribution at steady state [VSS] = 103 +/- 14 L) as well as on unbound plasma concentrations (plasma clearance of unbound drug [CLu] = 2.24 +/- 0.30 L/min; volume of distribution of unbound drug at steady state [Vuss] = 290 +/- 32 L), were larger (P < 0.0001) than those of S(+)-mepivacaine (CL = 0.35 +/- 0.06 L/min; Vss = 57 +/- 7 L; CLu = 1.43 +/- 0.24 L/ min; Vuss = 232 +/- 30 L).",Pharmacokinetics of the enantiomers of mepivacaine after intravenous administration of the racemate in volunteers. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8989005/),[l] / [min],1.43,40543,DB00961,Mepivacaine
,8989005,Vuss,"The total plasma clearance and steady-state volume of distribution of R(-)-mepivacaine, based on total plasma concentrations (total plasma clearance [CL] = 0.79 +/- 0.12 L/min; volume of distribution at steady state [VSS] = 103 +/- 14 L) as well as on unbound plasma concentrations (plasma clearance of unbound drug [CLu] = 2.24 +/- 0.30 L/min; volume of distribution of unbound drug at steady state [Vuss] = 290 +/- 32 L), were larger (P < 0.0001) than those of S(+)-mepivacaine (CL = 0.35 +/- 0.06 L/min; Vss = 57 +/- 7 L; CLu = 1.43 +/- 0.24 L/ min; Vuss = 232 +/- 30 L).",Pharmacokinetics of the enantiomers of mepivacaine after intravenous administration of the racemate in volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8989005/),l,232,40544,DB00961,Mepivacaine
,8989005,"t1/2,Z","The terminal half-life (t1/2,Z) and mean residence time (MRT) of R(-)-mepivacaine (t1/2,Z = 113 +/- 17 min; MRT = 131 +/- 15 min) were shorter than those of S(+)-mepivacaine (t1/2,Z = 123 +/- 20 min, P < 0.02; MRT = 165 +/- 24 min, P < 0.0001).",Pharmacokinetics of the enantiomers of mepivacaine after intravenous administration of the racemate in volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8989005/),min,113,40545,DB00961,Mepivacaine
,8989005,MRT,"The terminal half-life (t1/2,Z) and mean residence time (MRT) of R(-)-mepivacaine (t1/2,Z = 113 +/- 17 min; MRT = 131 +/- 15 min) were shorter than those of S(+)-mepivacaine (t1/2,Z = 123 +/- 20 min, P < 0.02; MRT = 165 +/- 24 min, P < 0.0001).",Pharmacokinetics of the enantiomers of mepivacaine after intravenous administration of the racemate in volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8989005/),min,131,40546,DB00961,Mepivacaine
,8989005,"t1/2,Z","The terminal half-life (t1/2,Z) and mean residence time (MRT) of R(-)-mepivacaine (t1/2,Z = 113 +/- 17 min; MRT = 131 +/- 15 min) were shorter than those of S(+)-mepivacaine (t1/2,Z = 123 +/- 20 min, P < 0.02; MRT = 165 +/- 24 min, P < 0.0001).",Pharmacokinetics of the enantiomers of mepivacaine after intravenous administration of the racemate in volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8989005/),min,123,40547,DB00961,Mepivacaine
,8989005,MRT,"The terminal half-life (t1/2,Z) and mean residence time (MRT) of R(-)-mepivacaine (t1/2,Z = 113 +/- 17 min; MRT = 131 +/- 15 min) were shorter than those of S(+)-mepivacaine (t1/2,Z = 123 +/- 20 min, P < 0.02; MRT = 165 +/- 24 min, P < 0.0001).",Pharmacokinetics of the enantiomers of mepivacaine after intravenous administration of the racemate in volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8989005/),min,165,40548,DB00961,Mepivacaine
,7793647,Cmax,Pharmacokinetic analysis showed that the Cmax was similar for both drugs (1.3 +/- 0.09 for ropivacaine and 1.1 +/- 0.09 micrograms/ml for bupivacaine).,Clinical effects and maternal and fetal plasma concentrations of epidural ropivacaine versus bupivacaine for cesarean section. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7793647/),[μg] / [ml],1.3,60262,DB00961,Mepivacaine
,7793647,Cmax,Pharmacokinetic analysis showed that the Cmax was similar for both drugs (1.3 +/- 0.09 for ropivacaine and 1.1 +/- 0.09 micrograms/ml for bupivacaine).,Clinical effects and maternal and fetal plasma concentrations of epidural ropivacaine versus bupivacaine for cesarean section. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7793647/),[μg] / [ml],1.1,60263,DB00961,Mepivacaine
,7793647,T1/2 of the terminal decline in plasma concentration,"The T1/2 of the terminal decline in plasma concentration was shorter for ropivacaine versus bupivacaine (5.2 +/- 0.60 versus 10.9 +/- 1.08 h, respectively; P < 0.01).",Clinical effects and maternal and fetal plasma concentrations of epidural ropivacaine versus bupivacaine for cesarean section. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7793647/),h,5.2,60264,DB00961,Mepivacaine
,7793647,T1/2 of the terminal decline in plasma concentration,"The T1/2 of the terminal decline in plasma concentration was shorter for ropivacaine versus bupivacaine (5.2 +/- 0.60 versus 10.9 +/- 1.08 h, respectively; P < 0.01).",Clinical effects and maternal and fetal plasma concentrations of epidural ropivacaine versus bupivacaine for cesarean section. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7793647/),h,10.9,60265,DB00961,Mepivacaine
,2271470,Cmax,"Plasma pharmacokinetic variables of mepivacaine were as follows: Cmax: 4.22 mg.l-1 (SD, 1.28); Tmax: 0.99 hours (SD, 0.76); T1/2: 3.25 hours (SD, 1.12); CL 0.55 1.hour-1.kg-1.",Plasma concentrations after high doses of mepivacaine with epinephrine in the combined psoas compartment/sciatic nerve block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2271470/),[mg] / [l],4.22,62610,DB00961,Mepivacaine
,2271470,Tmax,"Plasma pharmacokinetic variables of mepivacaine were as follows: Cmax: 4.22 mg.l-1 (SD, 1.28); Tmax: 0.99 hours (SD, 0.76); T1/2: 3.25 hours (SD, 1.12); CL 0.55 1.hour-1.kg-1.",Plasma concentrations after high doses of mepivacaine with epinephrine in the combined psoas compartment/sciatic nerve block. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2271470/),h,0.99,62611,DB00961,Mepivacaine
,2271470,T1/2,"Plasma pharmacokinetic variables of mepivacaine were as follows: Cmax: 4.22 mg.l-1 (SD, 1.28); Tmax: 0.99 hours (SD, 0.76); T1/2: 3.25 hours (SD, 1.12); CL 0.55 1.hour-1.kg-1.",Plasma concentrations after high doses of mepivacaine with epinephrine in the combined psoas compartment/sciatic nerve block. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2271470/),h,3.25,62612,DB00961,Mepivacaine
,2271470,CL,"Plasma pharmacokinetic variables of mepivacaine were as follows: Cmax: 4.22 mg.l-1 (SD, 1.28); Tmax: 0.99 hours (SD, 0.76); T1/2: 3.25 hours (SD, 1.12); CL 0.55 1.hour-1.kg-1.",Plasma concentrations after high doses of mepivacaine with epinephrine in the combined psoas compartment/sciatic nerve block. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2271470/),[1] / [h·kg],0.55,62613,DB00961,Mepivacaine
,1441871,maximum venous plasma concentrations,The mean maximum venous plasma concentrations of mepivacaine were more than twice as high as when prilocaine was used as anaesthetic (5.1 micrograms/ml vs. 2.37 micrograms/ml).,Plasma prilocaine and mepivacaine concentrations after combined lumbosacral plexus block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1441871/),[μg] / [ml],5.1,79761,DB00961,Mepivacaine
,1441871,maximum venous plasma concentrations,The mean maximum venous plasma concentrations of mepivacaine were more than twice as high as when prilocaine was used as anaesthetic (5.1 micrograms/ml vs. 2.37 micrograms/ml).,Plasma prilocaine and mepivacaine concentrations after combined lumbosacral plexus block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1441871/),[μg] / [ml],2.37,79762,DB00961,Mepivacaine
exceeded,1441871,peak plasma concentrations,The peak plasma concentrations exceeded the threshold of 5 micrograms/ml in four of the nine patients of the mepivacaine group (maximum value 7.21 mg/ml) and in two of the nine patients of the mepivacaine+ornipressin group (maximum value 8.61 micrograms/ml).,Plasma prilocaine and mepivacaine concentrations after combined lumbosacral plexus block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1441871/),[μg] / [ml],5,79763,DB00961,Mepivacaine
,1441871,peak plasma concentrations,The peak plasma concentrations exceeded the threshold of 5 micrograms/ml in four of the nine patients of the mepivacaine group (maximum value 7.21 mg/ml) and in two of the nine patients of the mepivacaine+ornipressin group (maximum value 8.61 micrograms/ml).,Plasma prilocaine and mepivacaine concentrations after combined lumbosacral plexus block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1441871/),[mg] / [ml],7.21,79764,DB00961,Mepivacaine
,1441871,peak plasma concentrations,The peak plasma concentrations exceeded the threshold of 5 micrograms/ml in four of the nine patients of the mepivacaine group (maximum value 7.21 mg/ml) and in two of the nine patients of the mepivacaine+ornipressin group (maximum value 8.61 micrograms/ml).,Plasma prilocaine and mepivacaine concentrations after combined lumbosacral plexus block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1441871/),[μg] / [ml],8.61,79765,DB00961,Mepivacaine
,1441871,maximum,The peak plasma concentrations exceeded the threshold of 5 micrograms/ml in four of the nine patients of the mepivacaine group (maximum value 7.21 mg/ml) and in two of the nine patients of the mepivacaine+ornipressin group (maximum value 8.61 micrograms/ml).,Plasma prilocaine and mepivacaine concentrations after combined lumbosacral plexus block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1441871/),[mg] / [ml],7.21,79766,DB00961,Mepivacaine
,1441871,maximum,The peak plasma concentrations exceeded the threshold of 5 micrograms/ml in four of the nine patients of the mepivacaine group (maximum value 7.21 mg/ml) and in two of the nine patients of the mepivacaine+ornipressin group (maximum value 8.61 micrograms/ml).,Plasma prilocaine and mepivacaine concentrations after combined lumbosacral plexus block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1441871/),[μg] / [ml],8.61,79767,DB00961,Mepivacaine
,18329563,Peak serum concentrations,"Peak serum concentrations of mepivacaine, C(max) (1.214 +/- 0.746 microg/mL(-1)), were significantly increased by propranolol (2.249 +/- 1.559 microg/mL(-1), P < .05).",Effect of propranolol on mepivacaine serum concentrations in dental practice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18329563/),[μg] / [ml],1.214,107406,DB00961,Mepivacaine
,18329563,Peak serum concentrations,"Peak serum concentrations of mepivacaine, C(max) (1.214 +/- 0.746 microg/mL(-1)), were significantly increased by propranolol (2.249 +/- 1.559 microg/mL(-1), P < .05).",Effect of propranolol on mepivacaine serum concentrations in dental practice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18329563/),[μg] / [ml],2.249,107407,DB00961,Mepivacaine
,18329563,C(max),"Peak serum concentrations of mepivacaine, C(max) (1.214 +/- 0.746 microg/mL(-1)), were significantly increased by propranolol (2.249 +/- 1.559 microg/mL(-1), P < .05).",Effect of propranolol on mepivacaine serum concentrations in dental practice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18329563/),[μg] / [ml],1.214,107408,DB00961,Mepivacaine
,18329563,C(max),"Peak serum concentrations of mepivacaine, C(max) (1.214 +/- 0.746 microg/mL(-1)), were significantly increased by propranolol (2.249 +/- 1.559 microg/mL(-1), P < .05).",Effect of propranolol on mepivacaine serum concentrations in dental practice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18329563/),[μg] / [ml],2.249,107409,DB00961,Mepivacaine
,24692782,serum Cmax,"The mean (SD) serum Cmax of tramadol was 1385.5 (390.8) ng/mL, Tmax was 0.33 (0.22) hour, and terminal elimination half-life (t1/2β) was 10.5 (2.3) hours.","Pharmacokinetics and postoperative analgesia of epidural tramadol: A prospective, pilot study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24692782/),[ng] / [ml],1385.5,124856,DB00961,Mepivacaine
,24692782,Tmax,"The mean (SD) serum Cmax of tramadol was 1385.5 (390.8) ng/mL, Tmax was 0.33 (0.22) hour, and terminal elimination half-life (t1/2β) was 10.5 (2.3) hours.","Pharmacokinetics and postoperative analgesia of epidural tramadol: A prospective, pilot study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24692782/),h,0.33,124857,DB00961,Mepivacaine
,24692782,terminal elimination half-life (t1/2β),"The mean (SD) serum Cmax of tramadol was 1385.5 (390.8) ng/mL, Tmax was 0.33 (0.22) hour, and terminal elimination half-life (t1/2β) was 10.5 (2.3) hours.","Pharmacokinetics and postoperative analgesia of epidural tramadol: A prospective, pilot study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24692782/),h,10.5,124858,DB00961,Mepivacaine
,1616166,maximal plasma concentration (Cmax),"The maximal plasma concentration (Cmax) of R(+) was 1.54 +/- 0.34 micrograms/mL, whereas that of the S(-) isomer was 2.34 +/- 0.51 micrograms/mL (P = 0.00050).",Clinical pharmacokinetics of R(+)- and S(-)-mepivacaine after high doses of racemic mepivacaine with epinephrine in the combined psoas compartment/sciatic nerve block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1616166/),[μg] / [ml],1.54,132107,DB00961,Mepivacaine
,1616166,maximal plasma concentration (Cmax),"The maximal plasma concentration (Cmax) of R(+) was 1.54 +/- 0.34 micrograms/mL, whereas that of the S(-) isomer was 2.34 +/- 0.51 micrograms/mL (P = 0.00050).",Clinical pharmacokinetics of R(+)- and S(-)-mepivacaine after high doses of racemic mepivacaine with epinephrine in the combined psoas compartment/sciatic nerve block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1616166/),[μg] / [ml],2.34,132108,DB00961,Mepivacaine
,1616166,elimination half-life (T1/2),"The elimination half-life (T1/2) was identical for both isomers (3 h), which means that the calculated total body clearance and the calculated steady-state volume of the distribution of R(+) are, respectively, 1.7 and 1.5 times larger than that of the S(-) isomer.",Clinical pharmacokinetics of R(+)- and S(-)-mepivacaine after high doses of racemic mepivacaine with epinephrine in the combined psoas compartment/sciatic nerve block. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1616166/),h,3,132109,DB00961,Mepivacaine
,2252168,"VD,ss","In this study, blood levels collected from 20 patients (36 +/- 19 y, 173 +/- 9 cm, 73 +/- 15 kg) after lumbar epidural anaesthesia with mepivacaine led to the development of a linear open one-compartment-model (VD,ss: 109 l, Cltot: 594 ml/min, t1/2abs: 13 min, t1/2 beta: 149 min).",[An infusion model for intraoperative peridural anesthesia by catheter using mepivacaine]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2252168/),l,109,138676,DB00961,Mepivacaine
,2252168,Cltot,"In this study, blood levels collected from 20 patients (36 +/- 19 y, 173 +/- 9 cm, 73 +/- 15 kg) after lumbar epidural anaesthesia with mepivacaine led to the development of a linear open one-compartment-model (VD,ss: 109 l, Cltot: 594 ml/min, t1/2abs: 13 min, t1/2 beta: 149 min).",[An infusion model for intraoperative peridural anesthesia by catheter using mepivacaine]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2252168/),[ml] / [min],594,138677,DB00961,Mepivacaine
,2252168,t1/2abs,"In this study, blood levels collected from 20 patients (36 +/- 19 y, 173 +/- 9 cm, 73 +/- 15 kg) after lumbar epidural anaesthesia with mepivacaine led to the development of a linear open one-compartment-model (VD,ss: 109 l, Cltot: 594 ml/min, t1/2abs: 13 min, t1/2 beta: 149 min).",[An infusion model for intraoperative peridural anesthesia by catheter using mepivacaine]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2252168/),min,13,138678,DB00961,Mepivacaine
,2252168,t1/2 beta,"In this study, blood levels collected from 20 patients (36 +/- 19 y, 173 +/- 9 cm, 73 +/- 15 kg) after lumbar epidural anaesthesia with mepivacaine led to the development of a linear open one-compartment-model (VD,ss: 109 l, Cltot: 594 ml/min, t1/2abs: 13 min, t1/2 beta: 149 min).",[An infusion model for intraoperative peridural anesthesia by catheter using mepivacaine]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2252168/),min,149,138679,DB00961,Mepivacaine
,2252168,maximum concentrations,"A mepivacaine dosage regimen for lumbar epidural anaesthesia, consisting of 250 mg as an initial bolus dose and an infusion rate of 150 mg/h after 15 min, cumulated to maximum concentrations of 2.5-3.5 micrograms/ml after 150 min.",[An infusion model for intraoperative peridural anesthesia by catheter using mepivacaine]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2252168/),[μg] / [ml],2.5-3.5,138680,DB00961,Mepivacaine
,15966499,half-lives of elimination (t1/2alpha,"The half-lives of elimination (t1/2alpha and t1/2beta) of articaine are 0.6 and 2.5 hours, whereas the apparent half-life of the metabolite articainic acid is 2.5 hours.",Clinical pharmacology and the use of articaine for local and regional anaesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15966499/),h,0.6,192815,DB00961,Mepivacaine
,15966499,t1/2beta),"The half-lives of elimination (t1/2alpha and t1/2beta) of articaine are 0.6 and 2.5 hours, whereas the apparent half-life of the metabolite articainic acid is 2.5 hours.",Clinical pharmacology and the use of articaine for local and regional anaesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15966499/),h,2.5,192816,DB00961,Mepivacaine
,15966499,apparent half-life,"The half-lives of elimination (t1/2alpha and t1/2beta) of articaine are 0.6 and 2.5 hours, whereas the apparent half-life of the metabolite articainic acid is 2.5 hours.",Clinical pharmacology and the use of articaine for local and regional anaesthesia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15966499/),h,2.5,192817,DB00961,Mepivacaine
,15966499,t1/2alpha,"Intrinsic half-lives of articainic acid are: t1/2alpha 12 minutes, and t1/2beta 64 minutes (1 hour).",Clinical pharmacology and the use of articaine for local and regional anaesthesia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15966499/),min,12,192818,DB00961,Mepivacaine
,15966499,t1/2beta,"Intrinsic half-lives of articainic acid are: t1/2alpha 12 minutes, and t1/2beta 64 minutes (1 hour).",Clinical pharmacology and the use of articaine for local and regional anaesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15966499/),min,64,192819,DB00961,Mepivacaine
,2098858,t max,Absorption from epidural space is equally fast for both anesthetic agents (t max 20 +/- 7 minutes for MPV and 25 +/- 12 minutes for LDC) resulting in high values of Cmax: 7.8 +/- 3.3 microg/ml for MPV and 2.6 +/- 0.7 microg/ml for LDC (p less than 0.001).,[Pharmacokinetics of mepivacaine and lidocaine after epidural administration]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2098858/),min,20,197017,DB00961,Mepivacaine
,2098858,t max,Absorption from epidural space is equally fast for both anesthetic agents (t max 20 +/- 7 minutes for MPV and 25 +/- 12 minutes for LDC) resulting in high values of Cmax: 7.8 +/- 3.3 microg/ml for MPV and 2.6 +/- 0.7 microg/ml for LDC (p less than 0.001).,[Pharmacokinetics of mepivacaine and lidocaine after epidural administration]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2098858/),min,25,197018,DB00961,Mepivacaine
,2098858,Cmax,Absorption from epidural space is equally fast for both anesthetic agents (t max 20 +/- 7 minutes for MPV and 25 +/- 12 minutes for LDC) resulting in high values of Cmax: 7.8 +/- 3.3 microg/ml for MPV and 2.6 +/- 0.7 microg/ml for LDC (p less than 0.001).,[Pharmacokinetics of mepivacaine and lidocaine after epidural administration]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2098858/),[μg] / [ml],7.8,197019,DB00961,Mepivacaine
,2098858,Cmax,Absorption from epidural space is equally fast for both anesthetic agents (t max 20 +/- 7 minutes for MPV and 25 +/- 12 minutes for LDC) resulting in high values of Cmax: 7.8 +/- 3.3 microg/ml for MPV and 2.6 +/- 0.7 microg/ml for LDC (p less than 0.001).,[Pharmacokinetics of mepivacaine and lidocaine after epidural administration]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2098858/),[μg] / [ml],2.6,197020,DB00961,Mepivacaine
,2098858,K,Mean values of K and Vd were 0.0076 +/- 0.0020 minutes-1 for MPV versus 0.0087 +/- 0.0032 minutes-1 for LDC and 0.9 +/- 0.7 1/kg for MPV versus 1.8 +/- 0.6 1/kg for LDC (p less than 0.001).,[Pharmacokinetics of mepivacaine and lidocaine after epidural administration]. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2098858/),1/[min],0.0076,197021,DB00961,Mepivacaine
,2098858,K,Mean values of K and Vd were 0.0076 +/- 0.0020 minutes-1 for MPV versus 0.0087 +/- 0.0032 minutes-1 for LDC and 0.9 +/- 0.7 1/kg for MPV versus 1.8 +/- 0.6 1/kg for LDC (p less than 0.001).,[Pharmacokinetics of mepivacaine and lidocaine after epidural administration]. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2098858/),1/[min],0.0087,197022,DB00961,Mepivacaine
,2098858,K,Mean values of K and Vd were 0.0076 +/- 0.0020 minutes-1 for MPV versus 0.0087 +/- 0.0032 minutes-1 for LDC and 0.9 +/- 0.7 1/kg for MPV versus 1.8 +/- 0.6 1/kg for LDC (p less than 0.001).,[Pharmacokinetics of mepivacaine and lidocaine after epidural administration]. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2098858/),[1] / [kg],0.9,197023,DB00961,Mepivacaine
,2098858,Vd,Mean values of K and Vd were 0.0076 +/- 0.0020 minutes-1 for MPV versus 0.0087 +/- 0.0032 minutes-1 for LDC and 0.9 +/- 0.7 1/kg for MPV versus 1.8 +/- 0.6 1/kg for LDC (p less than 0.001).,[Pharmacokinetics of mepivacaine and lidocaine after epidural administration]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2098858/),[1] / [kg],0.9,197024,DB00961,Mepivacaine
,2098858,Vd,Mean values of K and Vd were 0.0076 +/- 0.0020 minutes-1 for MPV versus 0.0087 +/- 0.0032 minutes-1 for LDC and 0.9 +/- 0.7 1/kg for MPV versus 1.8 +/- 0.6 1/kg for LDC (p less than 0.001).,[Pharmacokinetics of mepivacaine and lidocaine after epidural administration]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2098858/),[1] / [kg],1.8,197025,DB00961,Mepivacaine
,3320904,retention times,"Under the conditions of the assay used, retention times were 3.3 minutes and 6.3 minutes for mepivacaine and bupivacaine, respectively.",[Pharmacokinetic study of bupivacaine in mice: proposal of a specific sensitive technic using gas chromatography]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3320904/),min,3.3,201726,DB00961,Mepivacaine
,3320904,retention times,"Under the conditions of the assay used, retention times were 3.3 minutes and 6.3 minutes for mepivacaine and bupivacaine, respectively.",[Pharmacokinetic study of bupivacaine in mice: proposal of a specific sensitive technic using gas chromatography]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3320904/),min,6.3,201727,DB00961,Mepivacaine
,9425973,Arterial plasma me,"Arterial plasma mepivacaine concentrations were higher after extrasheath injection [8.0 (6.3-9.7) vs 5.8 (4.5-7.0), microg/mL, means (95% confidence intervals), P < .05].",Failed axillary brachial plexus block techniques result in high plasma concentrations of mepivacaine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9425973/),"[,·μg] / [ml]",8.0,214759,DB00961,Mepivacaine
,9425973,Arterial plasma me,"Arterial plasma mepivacaine concentrations were higher after extrasheath injection [8.0 (6.3-9.7) vs 5.8 (4.5-7.0), microg/mL, means (95% confidence intervals), P < .05].",Failed axillary brachial plexus block techniques result in high plasma concentrations of mepivacaine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9425973/),"[,·μg] / [ml]",5.8,214760,DB00961,Mepivacaine
,9425973,concentrations,"Arterial plasma mepivacaine concentrations were higher after extrasheath injection [8.0 (6.3-9.7) vs 5.8 (4.5-7.0), microg/mL, means (95% confidence intervals), P < .05].",Failed axillary brachial plexus block techniques result in high plasma concentrations of mepivacaine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9425973/),"[,·μg] / [ml]",8.0,214761,DB00961,Mepivacaine
,9425973,concentrations,"Arterial plasma mepivacaine concentrations were higher after extrasheath injection [8.0 (6.3-9.7) vs 5.8 (4.5-7.0), microg/mL, means (95% confidence intervals), P < .05].",Failed axillary brachial plexus block techniques result in high plasma concentrations of mepivacaine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9425973/),"[,·μg] / [ml]",5.8,214762,DB00961,Mepivacaine
,2589653,blood clearance,Its blood clearance (0.72 +/- 0.16 L/min) is intermediate between that of mepivacaine and bupivacaine.,Disposition kinetics of ropivacaine in humans. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2589653/),[l] / [min],0.72,223615,DB00961,Mepivacaine
,2589653,Plasma binding,Plasma binding averaged 94% +/- 1% and the volume of distribution at steady state based on blood drug concentration was 59 +/- 7 L.,Disposition kinetics of ropivacaine in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2589653/),%,94,223616,DB00961,Mepivacaine
,2589653,volume of distribution at steady state,Plasma binding averaged 94% +/- 1% and the volume of distribution at steady state based on blood drug concentration was 59 +/- 7 L.,Disposition kinetics of ropivacaine in humans. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2589653/),l,59,223617,DB00961,Mepivacaine
,2589653,terminal elimination half-life,The terminal elimination half-life was 111 +/- 62 min.,Disposition kinetics of ropivacaine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2589653/),min,111,223618,DB00961,Mepivacaine
,12805913,t1/2alpha,Lidocaine is eliminated biexponentially with a t1/2alpha of 9.95 +/- 14.3 min and a t1/2beta of 2.86 +/- 1.55 h.,Similar motor block effects and disposition kinetics between lidocaine and (+/-)mepivacaine in patients undergoing axillary brachial plexus block during day case surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12805913/),min,9.95,225154,DB00961,Mepivacaine
,12805913,t1/2beta,Lidocaine is eliminated biexponentially with a t1/2alpha of 9.95 +/- 14.3 min and a t1/2beta of 2.86 +/- 1.55 h.,Similar motor block effects and disposition kinetics between lidocaine and (+/-)mepivacaine in patients undergoing axillary brachial plexus block during day case surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12805913/),h,2.86,225155,DB00961,Mepivacaine
,12805913,tmax,Lidocaine is metabolised into MEGX (tmax 2.31 +/- 0.84 h; Cmax 0.32 +/- 0.13 mg l(-1); t1/2beta 2.36 +/- 2.35 h; total body clearance was 67.9 +/- 28.9 l h(-1)).,Similar motor block effects and disposition kinetics between lidocaine and (+/-)mepivacaine in patients undergoing axillary brachial plexus block during day case surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12805913/),h,2.31,225156,DB00961,Mepivacaine
,12805913,Cmax,Lidocaine is metabolised into MEGX (tmax 2.31 +/- 0.84 h; Cmax 0.32 +/- 0.13 mg l(-1); t1/2beta 2.36 +/- 2.35 h; total body clearance was 67.9 +/- 28.9 l h(-1)).,Similar motor block effects and disposition kinetics between lidocaine and (+/-)mepivacaine in patients undergoing axillary brachial plexus block during day case surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12805913/),[mg] / [l],0.32,225157,DB00961,Mepivacaine
,12805913,t1/2beta,Lidocaine is metabolised into MEGX (tmax 2.31 +/- 0.84 h; Cmax 0.32 +/- 0.13 mg l(-1); t1/2beta 2.36 +/- 2.35 h; total body clearance was 67.9 +/- 28.9 l h(-1)).,Similar motor block effects and disposition kinetics between lidocaine and (+/-)mepivacaine in patients undergoing axillary brachial plexus block during day case surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12805913/),h,2.36,225158,DB00961,Mepivacaine
,12805913,total body clearance,Lidocaine is metabolised into MEGX (tmax 2.31 +/- 0.84 h; Cmax 0.32 +/- 0.13 mg l(-1); t1/2beta 2.36 +/- 2.35 h; total body clearance was 67.9 +/- 28.9 l h(-1)).,Similar motor block effects and disposition kinetics between lidocaine and (+/-)mepivacaine in patients undergoing axillary brachial plexus block during day case surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12805913/),[l] / [h],67.9,225159,DB00961,Mepivacaine
,12805913,t1/2,"Mepivacaine is eliminated rapidly and monoexponentially with a t1/2 of 4.78 +/- 2.38 h, a Cmax of 3.89 +/- 0.83 mg l(-1), and a tmax of 0.41 +/- 0.19 h.",Similar motor block effects and disposition kinetics between lidocaine and (+/-)mepivacaine in patients undergoing axillary brachial plexus block during day case surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12805913/),h,4.78,225160,DB00961,Mepivacaine
,12805913,Cmax,"Mepivacaine is eliminated rapidly and monoexponentially with a t1/2 of 4.78 +/- 2.38 h, a Cmax of 3.89 +/- 0.83 mg l(-1), and a tmax of 0.41 +/- 0.19 h.",Similar motor block effects and disposition kinetics between lidocaine and (+/-)mepivacaine in patients undergoing axillary brachial plexus block during day case surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12805913/),[mg] / [l],3.89,225161,DB00961,Mepivacaine
,12805913,tmax,"Mepivacaine is eliminated rapidly and monoexponentially with a t1/2 of 4.78 +/- 2.38 h, a Cmax of 3.89 +/- 0.83 mg l(-1), and a tmax of 0.41 +/- 0.19 h.",Similar motor block effects and disposition kinetics between lidocaine and (+/-)mepivacaine in patients undergoing axillary brachial plexus block during day case surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12805913/),h,0.41,225162,DB00961,Mepivacaine
,12805913,total body clearance,"The total body clearance of mepivacaine is 50% of that of lidocaine, 26.9 +/- 10.6 l h(-1) vs. 67.9 +/- 28.9 l h-1, respectively (p < 0.0001).",Similar motor block effects and disposition kinetics between lidocaine and (+/-)mepivacaine in patients undergoing axillary brachial plexus block during day case surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12805913/),[l] / [h],26.9,225163,DB00961,Mepivacaine
,12805913,total body clearance,"The total body clearance of mepivacaine is 50% of that of lidocaine, 26.9 +/- 10.6 l h(-1) vs. 67.9 +/- 28.9 l h-1, respectively (p < 0.0001).",Similar motor block effects and disposition kinetics between lidocaine and (+/-)mepivacaine in patients undergoing axillary brachial plexus block during day case surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12805913/),[l] / [h],67.9,225164,DB00961,Mepivacaine
,12805913,Cmax,"(+/-)mepivacaine is metabolised into (+/-)4-OHmepivacaine (Cmax 0.45 +/- 0.25 mg l(-1); t1/2beta 6.48 +/- 6.57 h) and (+/-)2,6-pipecoloxylidide (Cmax 0.56 +/- 0.30 mg l(-1); t1/2beta 1.48 +/- 0.74 h).",Similar motor block effects and disposition kinetics between lidocaine and (+/-)mepivacaine in patients undergoing axillary brachial plexus block during day case surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12805913/),[mg] / [l],0.45,225165,DB00961,Mepivacaine
,12805913,t1/2beta,"(+/-)mepivacaine is metabolised into (+/-)4-OHmepivacaine (Cmax 0.45 +/- 0.25 mg l(-1); t1/2beta 6.48 +/- 6.57 h) and (+/-)2,6-pipecoloxylidide (Cmax 0.56 +/- 0.30 mg l(-1); t1/2beta 1.48 +/- 0.74 h).",Similar motor block effects and disposition kinetics between lidocaine and (+/-)mepivacaine in patients undergoing axillary brachial plexus block during day case surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12805913/),h,6.48,225166,DB00961,Mepivacaine
,12805913,Cmax,"(+/-)mepivacaine is metabolised into (+/-)4-OHmepivacaine (Cmax 0.45 +/- 0.25 mg l(-1); t1/2beta 6.48 +/- 6.57 h) and (+/-)2,6-pipecoloxylidide (Cmax 0.56 +/- 0.30 mg l(-1); t1/2beta 1.48 +/- 0.74 h).",Similar motor block effects and disposition kinetics between lidocaine and (+/-)mepivacaine in patients undergoing axillary brachial plexus block during day case surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12805913/),[mg] / [l],0.56,225167,DB00961,Mepivacaine
,12805913,t1/2beta,"(+/-)mepivacaine is metabolised into (+/-)4-OHmepivacaine (Cmax 0.45 +/- 0.25 mg l(-1); t1/2beta 6.48 +/- 6.57 h) and (+/-)2,6-pipecoloxylidide (Cmax 0.56 +/- 0.30 mg l(-1); t1/2beta 1.48 +/- 0.74 h).",Similar motor block effects and disposition kinetics between lidocaine and (+/-)mepivacaine in patients undergoing axillary brachial plexus block during day case surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12805913/),h,1.48,225168,DB00961,Mepivacaine
,1911009,total body clearance,"For R(-)-and S(+)-mepivacaine, respective mean (SEM) values of parameters were: total body clearance 1.20 (0.29) litre min-1 and 0.97 (0.20) litre min-1 (ns); total volume of distribution 144 (39) litre and 80 (21) litre (P less than 0.05); slow half-life 120 (40) min and 84 (22) min (ns); mean hepatic extraction ratio 0.50 (0.14) and 0.52 (0.09) (ns); mean hepatic clearance 0.75 (0.23) litre min-1 and 0.75 (0.18) litre min-1 (ns).",Disposition of mepivacaine and bupivacaine enantiomers in sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911009/),[l] / [min],1.20,230175,DB00961,Mepivacaine
,1911009,total body clearance,"For R(-)-and S(+)-mepivacaine, respective mean (SEM) values of parameters were: total body clearance 1.20 (0.29) litre min-1 and 0.97 (0.20) litre min-1 (ns); total volume of distribution 144 (39) litre and 80 (21) litre (P less than 0.05); slow half-life 120 (40) min and 84 (22) min (ns); mean hepatic extraction ratio 0.50 (0.14) and 0.52 (0.09) (ns); mean hepatic clearance 0.75 (0.23) litre min-1 and 0.75 (0.18) litre min-1 (ns).",Disposition of mepivacaine and bupivacaine enantiomers in sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911009/),[l] / [min],0.97,230176,DB00961,Mepivacaine
,1911009,total volume of distribution,"For R(-)-and S(+)-mepivacaine, respective mean (SEM) values of parameters were: total body clearance 1.20 (0.29) litre min-1 and 0.97 (0.20) litre min-1 (ns); total volume of distribution 144 (39) litre and 80 (21) litre (P less than 0.05); slow half-life 120 (40) min and 84 (22) min (ns); mean hepatic extraction ratio 0.50 (0.14) and 0.52 (0.09) (ns); mean hepatic clearance 0.75 (0.23) litre min-1 and 0.75 (0.18) litre min-1 (ns).",Disposition of mepivacaine and bupivacaine enantiomers in sheep. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911009/),l,144,230177,DB00961,Mepivacaine
,1911009,total volume of distribution,"For R(-)-and S(+)-mepivacaine, respective mean (SEM) values of parameters were: total body clearance 1.20 (0.29) litre min-1 and 0.97 (0.20) litre min-1 (ns); total volume of distribution 144 (39) litre and 80 (21) litre (P less than 0.05); slow half-life 120 (40) min and 84 (22) min (ns); mean hepatic extraction ratio 0.50 (0.14) and 0.52 (0.09) (ns); mean hepatic clearance 0.75 (0.23) litre min-1 and 0.75 (0.18) litre min-1 (ns).",Disposition of mepivacaine and bupivacaine enantiomers in sheep. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911009/),l,80,230178,DB00961,Mepivacaine
,1911009,slow half-life,"For R(-)-and S(+)-mepivacaine, respective mean (SEM) values of parameters were: total body clearance 1.20 (0.29) litre min-1 and 0.97 (0.20) litre min-1 (ns); total volume of distribution 144 (39) litre and 80 (21) litre (P less than 0.05); slow half-life 120 (40) min and 84 (22) min (ns); mean hepatic extraction ratio 0.50 (0.14) and 0.52 (0.09) (ns); mean hepatic clearance 0.75 (0.23) litre min-1 and 0.75 (0.18) litre min-1 (ns).",Disposition of mepivacaine and bupivacaine enantiomers in sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911009/),min,120,230179,DB00961,Mepivacaine
,1911009,slow half-life,"For R(-)-and S(+)-mepivacaine, respective mean (SEM) values of parameters were: total body clearance 1.20 (0.29) litre min-1 and 0.97 (0.20) litre min-1 (ns); total volume of distribution 144 (39) litre and 80 (21) litre (P less than 0.05); slow half-life 120 (40) min and 84 (22) min (ns); mean hepatic extraction ratio 0.50 (0.14) and 0.52 (0.09) (ns); mean hepatic clearance 0.75 (0.23) litre min-1 and 0.75 (0.18) litre min-1 (ns).",Disposition of mepivacaine and bupivacaine enantiomers in sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911009/),min,84,230180,DB00961,Mepivacaine
,1911009,hepatic extraction ratio,"For R(-)-and S(+)-mepivacaine, respective mean (SEM) values of parameters were: total body clearance 1.20 (0.29) litre min-1 and 0.97 (0.20) litre min-1 (ns); total volume of distribution 144 (39) litre and 80 (21) litre (P less than 0.05); slow half-life 120 (40) min and 84 (22) min (ns); mean hepatic extraction ratio 0.50 (0.14) and 0.52 (0.09) (ns); mean hepatic clearance 0.75 (0.23) litre min-1 and 0.75 (0.18) litre min-1 (ns).",Disposition of mepivacaine and bupivacaine enantiomers in sheep. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911009/),,0.50,230181,DB00961,Mepivacaine
,1911009,hepatic extraction ratio,"For R(-)-and S(+)-mepivacaine, respective mean (SEM) values of parameters were: total body clearance 1.20 (0.29) litre min-1 and 0.97 (0.20) litre min-1 (ns); total volume of distribution 144 (39) litre and 80 (21) litre (P less than 0.05); slow half-life 120 (40) min and 84 (22) min (ns); mean hepatic extraction ratio 0.50 (0.14) and 0.52 (0.09) (ns); mean hepatic clearance 0.75 (0.23) litre min-1 and 0.75 (0.18) litre min-1 (ns).",Disposition of mepivacaine and bupivacaine enantiomers in sheep. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911009/),,0.52,230182,DB00961,Mepivacaine
,1911009,hepatic clearance,"For R(-)-and S(+)-mepivacaine, respective mean (SEM) values of parameters were: total body clearance 1.20 (0.29) litre min-1 and 0.97 (0.20) litre min-1 (ns); total volume of distribution 144 (39) litre and 80 (21) litre (P less than 0.05); slow half-life 120 (40) min and 84 (22) min (ns); mean hepatic extraction ratio 0.50 (0.14) and 0.52 (0.09) (ns); mean hepatic clearance 0.75 (0.23) litre min-1 and 0.75 (0.18) litre min-1 (ns).",Disposition of mepivacaine and bupivacaine enantiomers in sheep. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911009/),[l] / [min],0.75,230183,DB00961,Mepivacaine
,1911009,hepatic clearance,"For R(-)-and S(+)-mepivacaine, respective mean (SEM) values of parameters were: total body clearance 1.20 (0.29) litre min-1 and 0.97 (0.20) litre min-1 (ns); total volume of distribution 144 (39) litre and 80 (21) litre (P less than 0.05); slow half-life 120 (40) min and 84 (22) min (ns); mean hepatic extraction ratio 0.50 (0.14) and 0.52 (0.09) (ns); mean hepatic clearance 0.75 (0.23) litre min-1 and 0.75 (0.18) litre min-1 (ns).",Disposition of mepivacaine and bupivacaine enantiomers in sheep. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911009/),[l] / [min],0.75,230184,DB00961,Mepivacaine
,1911009,total body clearance,"For R(+)- and S(-)-bupivacaine, respective values were: total body clearance 0.77 (0.33) litre min-1 and 0.53 (0.26) litre min-1 (P less than 0.05); total volume of distribution 40 (10) litre and 43 (10) litre (ns); slow half-life 57 (10) min and 104 (21) min (P less than 0.05); mean hepatic extraction ratio 0.46 (0.15) and 0.29 (0.13) (P less than 0.05); mean hepatic clearance 0.85 (0.31) litre min-1 and 0.54 (0.26) litre min-1 (P less than 0.05).",Disposition of mepivacaine and bupivacaine enantiomers in sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911009/),[l] / [min],0.77,230185,DB00961,Mepivacaine
,1911009,total body clearance,"For R(+)- and S(-)-bupivacaine, respective values were: total body clearance 0.77 (0.33) litre min-1 and 0.53 (0.26) litre min-1 (P less than 0.05); total volume of distribution 40 (10) litre and 43 (10) litre (ns); slow half-life 57 (10) min and 104 (21) min (P less than 0.05); mean hepatic extraction ratio 0.46 (0.15) and 0.29 (0.13) (P less than 0.05); mean hepatic clearance 0.85 (0.31) litre min-1 and 0.54 (0.26) litre min-1 (P less than 0.05).",Disposition of mepivacaine and bupivacaine enantiomers in sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911009/),[l] / [min],0.53,230186,DB00961,Mepivacaine
,1911009,total volume of distribution,"For R(+)- and S(-)-bupivacaine, respective values were: total body clearance 0.77 (0.33) litre min-1 and 0.53 (0.26) litre min-1 (P less than 0.05); total volume of distribution 40 (10) litre and 43 (10) litre (ns); slow half-life 57 (10) min and 104 (21) min (P less than 0.05); mean hepatic extraction ratio 0.46 (0.15) and 0.29 (0.13) (P less than 0.05); mean hepatic clearance 0.85 (0.31) litre min-1 and 0.54 (0.26) litre min-1 (P less than 0.05).",Disposition of mepivacaine and bupivacaine enantiomers in sheep. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911009/),l,40,230187,DB00961,Mepivacaine
,1911009,total volume of distribution,"For R(+)- and S(-)-bupivacaine, respective values were: total body clearance 0.77 (0.33) litre min-1 and 0.53 (0.26) litre min-1 (P less than 0.05); total volume of distribution 40 (10) litre and 43 (10) litre (ns); slow half-life 57 (10) min and 104 (21) min (P less than 0.05); mean hepatic extraction ratio 0.46 (0.15) and 0.29 (0.13) (P less than 0.05); mean hepatic clearance 0.85 (0.31) litre min-1 and 0.54 (0.26) litre min-1 (P less than 0.05).",Disposition of mepivacaine and bupivacaine enantiomers in sheep. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911009/),l,43,230188,DB00961,Mepivacaine
,1911009,slow half-life,"For R(+)- and S(-)-bupivacaine, respective values were: total body clearance 0.77 (0.33) litre min-1 and 0.53 (0.26) litre min-1 (P less than 0.05); total volume of distribution 40 (10) litre and 43 (10) litre (ns); slow half-life 57 (10) min and 104 (21) min (P less than 0.05); mean hepatic extraction ratio 0.46 (0.15) and 0.29 (0.13) (P less than 0.05); mean hepatic clearance 0.85 (0.31) litre min-1 and 0.54 (0.26) litre min-1 (P less than 0.05).",Disposition of mepivacaine and bupivacaine enantiomers in sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911009/),min,57,230189,DB00961,Mepivacaine
,1911009,slow half-life,"For R(+)- and S(-)-bupivacaine, respective values were: total body clearance 0.77 (0.33) litre min-1 and 0.53 (0.26) litre min-1 (P less than 0.05); total volume of distribution 40 (10) litre and 43 (10) litre (ns); slow half-life 57 (10) min and 104 (21) min (P less than 0.05); mean hepatic extraction ratio 0.46 (0.15) and 0.29 (0.13) (P less than 0.05); mean hepatic clearance 0.85 (0.31) litre min-1 and 0.54 (0.26) litre min-1 (P less than 0.05).",Disposition of mepivacaine and bupivacaine enantiomers in sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911009/),min,104,230190,DB00961,Mepivacaine
,1911009,hepatic extraction ratio,"For R(+)- and S(-)-bupivacaine, respective values were: total body clearance 0.77 (0.33) litre min-1 and 0.53 (0.26) litre min-1 (P less than 0.05); total volume of distribution 40 (10) litre and 43 (10) litre (ns); slow half-life 57 (10) min and 104 (21) min (P less than 0.05); mean hepatic extraction ratio 0.46 (0.15) and 0.29 (0.13) (P less than 0.05); mean hepatic clearance 0.85 (0.31) litre min-1 and 0.54 (0.26) litre min-1 (P less than 0.05).",Disposition of mepivacaine and bupivacaine enantiomers in sheep. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911009/),,0.46,230191,DB00961,Mepivacaine
,1911009,hepatic extraction ratio,"For R(+)- and S(-)-bupivacaine, respective values were: total body clearance 0.77 (0.33) litre min-1 and 0.53 (0.26) litre min-1 (P less than 0.05); total volume of distribution 40 (10) litre and 43 (10) litre (ns); slow half-life 57 (10) min and 104 (21) min (P less than 0.05); mean hepatic extraction ratio 0.46 (0.15) and 0.29 (0.13) (P less than 0.05); mean hepatic clearance 0.85 (0.31) litre min-1 and 0.54 (0.26) litre min-1 (P less than 0.05).",Disposition of mepivacaine and bupivacaine enantiomers in sheep. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911009/),,0.29,230192,DB00961,Mepivacaine
,1911009,hepatic clearance,"For R(+)- and S(-)-bupivacaine, respective values were: total body clearance 0.77 (0.33) litre min-1 and 0.53 (0.26) litre min-1 (P less than 0.05); total volume of distribution 40 (10) litre and 43 (10) litre (ns); slow half-life 57 (10) min and 104 (21) min (P less than 0.05); mean hepatic extraction ratio 0.46 (0.15) and 0.29 (0.13) (P less than 0.05); mean hepatic clearance 0.85 (0.31) litre min-1 and 0.54 (0.26) litre min-1 (P less than 0.05).",Disposition of mepivacaine and bupivacaine enantiomers in sheep. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911009/),[l] / [min],0.85,230193,DB00961,Mepivacaine
,1911009,hepatic clearance,"For R(+)- and S(-)-bupivacaine, respective values were: total body clearance 0.77 (0.33) litre min-1 and 0.53 (0.26) litre min-1 (P less than 0.05); total volume of distribution 40 (10) litre and 43 (10) litre (ns); slow half-life 57 (10) min and 104 (21) min (P less than 0.05); mean hepatic extraction ratio 0.46 (0.15) and 0.29 (0.13) (P less than 0.05); mean hepatic clearance 0.85 (0.31) litre min-1 and 0.54 (0.26) litre min-1 (P less than 0.05).",Disposition of mepivacaine and bupivacaine enantiomers in sheep. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911009/),[l] / [min],0.54,230194,DB00961,Mepivacaine
,2960397,Bioavailability,"Bioavailability of lidocaine in 5 normal volunteers ranged from 26 to 36% (mean 31 +/- SD 5%) and in a cirrhotic with an end-to-side portacaval shunt it approached 100%, as anticipated.",Bioavailability determination of lidocaine by capillary gas chromatography ammonia chemical ionization mass spectrometry. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2960397/),%,26 to 36,235514,DB00961,Mepivacaine
,2960397,Bioavailability,"Bioavailability of lidocaine in 5 normal volunteers ranged from 26 to 36% (mean 31 +/- SD 5%) and in a cirrhotic with an end-to-side portacaval shunt it approached 100%, as anticipated.",Bioavailability determination of lidocaine by capillary gas chromatography ammonia chemical ionization mass spectrometry. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2960397/),%,31,235515,DB00961,Mepivacaine
,2960397,Bioavailability,"Bioavailability of lidocaine in 5 normal volunteers ranged from 26 to 36% (mean 31 +/- SD 5%) and in a cirrhotic with an end-to-side portacaval shunt it approached 100%, as anticipated.",Bioavailability determination of lidocaine by capillary gas chromatography ammonia chemical ionization mass spectrometry. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2960397/),%,100,235516,DB00961,Mepivacaine
,27976931,t1/2,"For the pharmacokinetic analysis of plasma, the mean (SD) values obtained were as follows: t1/2, 1.63 (0.43) h; Cmax, 435.3 (67.4) ng/ml; AUC0-t, 1546.9 (339.7) ng/ml·h; AUC0-∞, 1982.3 (421.4) ng/ml·h; Tmax, 0.62 (0.31) h.",A novel LC-MS/MS method for mepivacaine determination and pharmacokinetic study in a single-dose two-period crossover in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27976931/),h,1.63,240150,DB00961,Mepivacaine
,27976931,Cmax,"For the pharmacokinetic analysis of plasma, the mean (SD) values obtained were as follows: t1/2, 1.63 (0.43) h; Cmax, 435.3 (67.4) ng/ml; AUC0-t, 1546.9 (339.7) ng/ml·h; AUC0-∞, 1982.3 (421.4) ng/ml·h; Tmax, 0.62 (0.31) h.",A novel LC-MS/MS method for mepivacaine determination and pharmacokinetic study in a single-dose two-period crossover in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27976931/),[ng] / [ml],435.3,240151,DB00961,Mepivacaine
,27976931,AUC0-t,"For the pharmacokinetic analysis of plasma, the mean (SD) values obtained were as follows: t1/2, 1.63 (0.43) h; Cmax, 435.3 (67.4) ng/ml; AUC0-t, 1546.9 (339.7) ng/ml·h; AUC0-∞, 1982.3 (421.4) ng/ml·h; Tmax, 0.62 (0.31) h.",A novel LC-MS/MS method for mepivacaine determination and pharmacokinetic study in a single-dose two-period crossover in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27976931/),[ng] / [h·ml],1546.9,240152,DB00961,Mepivacaine
,27976931,AUC0-∞,"For the pharmacokinetic analysis of plasma, the mean (SD) values obtained were as follows: t1/2, 1.63 (0.43) h; Cmax, 435.3 (67.4) ng/ml; AUC0-t, 1546.9 (339.7) ng/ml·h; AUC0-∞, 1982.3 (421.4) ng/ml·h; Tmax, 0.62 (0.31) h.",A novel LC-MS/MS method for mepivacaine determination and pharmacokinetic study in a single-dose two-period crossover in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27976931/),[ng] / [h·ml],1982.3,240153,DB00961,Mepivacaine
,27976931,Tmax,"For the pharmacokinetic analysis of plasma, the mean (SD) values obtained were as follows: t1/2, 1.63 (0.43) h; Cmax, 435.3 (67.4) ng/ml; AUC0-t, 1546.9 (339.7) ng/ml·h; AUC0-∞, 1982.3 (421.4) ng/ml·h; Tmax, 0.62 (0.31) h.",A novel LC-MS/MS method for mepivacaine determination and pharmacokinetic study in a single-dose two-period crossover in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27976931/),h,0.62,240154,DB00961,Mepivacaine
,8150879,extraction yield,"The extraction yield of bupivacaine from plasma was 73.5 +/- 5.1% (mean +/- S.D., n = 10).",High-performance liquid chromatographic determination of bupivacaine in plasma samples for biopharmaceutical studies and application to seven other local anaesthetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8150879/),%,73.5,253252,DB00961,Mepivacaine
,8150879,signal-to-noise ratio,"The limit of detection, defined by a signal-to-noise ratio of 3:1, was 2 ng/ml.",High-performance liquid chromatographic determination of bupivacaine in plasma samples for biopharmaceutical studies and application to seven other local anaesthetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8150879/),[ng] / [ml],3:1,253253,DB00961,Mepivacaine
,8150879,signal-to-noise ratio,"The limit of detection, defined by a signal-to-noise ratio of 3:1, was 2 ng/ml.",High-performance liquid chromatographic determination of bupivacaine in plasma samples for biopharmaceutical studies and application to seven other local anaesthetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8150879/),[ng] / [ml],2,253254,DB00961,Mepivacaine
,25159439,flow rate,"The chromatographic separation was achieved on Gemini C18 column using a mobile phase of ACN: 30 mmol L(-1) potassium dihydrogen phosphate buffer containing 0.1% triethylamine, pH 3.5 (20:80, v/v) at a flow rate of 1 mL min(-1) and UV detection at 254 and 295 nm for DOR and TIM, respectively.",Simultaneous determination of dorzolomide and timolol in aqueous humor: a novel salting out liquid-liquid microextraction combined with HPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25159439/),[ml] / [min],1,257449,DB00961,Mepivacaine
,25159439,limits of quantitation,"The described method showed better separation with enhanced sensitivities than the previously reported methods with limits of quantitation of 8.75 and 10.32 ng mL(-1) in aqueous solution and 15.97 and 23.53 ng mL(-1) in AH for DOR and TIM, respectively.",Simultaneous determination of dorzolomide and timolol in aqueous humor: a novel salting out liquid-liquid microextraction combined with HPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25159439/),[ng] / [ml],8.75,257450,DB00961,Mepivacaine
,25159439,limits of quantitation,"The described method showed better separation with enhanced sensitivities than the previously reported methods with limits of quantitation of 8.75 and 10.32 ng mL(-1) in aqueous solution and 15.97 and 23.53 ng mL(-1) in AH for DOR and TIM, respectively.",Simultaneous determination of dorzolomide and timolol in aqueous humor: a novel salting out liquid-liquid microextraction combined with HPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25159439/),[ng] / [ml],10.32,257451,DB00961,Mepivacaine
,25159439,limits of quantitation,"The described method showed better separation with enhanced sensitivities than the previously reported methods with limits of quantitation of 8.75 and 10.32 ng mL(-1) in aqueous solution and 15.97 and 23.53 ng mL(-1) in AH for DOR and TIM, respectively.",Simultaneous determination of dorzolomide and timolol in aqueous humor: a novel salting out liquid-liquid microextraction combined with HPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25159439/),[ng] / [ml],15.97,257452,DB00961,Mepivacaine
,25159439,limits of quantitation,"The described method showed better separation with enhanced sensitivities than the previously reported methods with limits of quantitation of 8.75 and 10.32 ng mL(-1) in aqueous solution and 15.97 and 23.53 ng mL(-1) in AH for DOR and TIM, respectively.",Simultaneous determination of dorzolomide and timolol in aqueous humor: a novel salting out liquid-liquid microextraction combined with HPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25159439/),[ng] / [ml],23.53,257453,DB00961,Mepivacaine
